Feature

Medical marijuana’s ‘Catch-22’: Federal limits on research hinder patients’ relief


 


The Trump administration, however, has resisted policy changes.

Last year, the Drug Enforcement Administration had been gearing up to allow facilities other than the University of Mississippi to grow pot for research. But after the DEA received 26 applications from other growers, Attorney General Jeff Sessions halted the initiative.

The Department of Veterans Affairs also recently announced it would not fund studies of using marijuana compounds to treat ailments such as pain.

The DEA and HHS have cited concerns about medical supervision, addiction, and a lack of “well-controlled studies proving efficacy.”

Patients, meanwhile, forge ahead.

While experts say they don’t know exactly how many older Americans rely on marijuana for medicinal purposes, the number of Americans aged 65 years and older who say they are using the drug skyrocketed 250% from 2006 to 2013.

Some patients turn to friends, patient advocacy groups, or online support groups for information.

Pages

Recommended Reading

Mortality rate was 10-fold higher in opioid use disorder patients
MDedge Infectious Disease
The latest news on pediatric migraine
MDedge Infectious Disease
‘Chronic Lyme’: Serious bacterial infections reported with unproven treatments
MDedge Infectious Disease
Adjuvant-boosted shingles vaccine earns FDA panel’s unanimous nod
MDedge Infectious Disease
Post-Ebola syndrome includes neurologic sequelae
MDedge Infectious Disease
In close vote, advisory panel prefers Shingrix over Zostavax
MDedge Infectious Disease
Novel herpes zoster vaccine is more cost effective than old vaccine
MDedge Infectious Disease
MDedge Daily News: Why the barber’s chair can help hypertension
MDedge Infectious Disease
MDedge Daily News: Does more marijuana mean fewer opioids?
MDedge Infectious Disease
Life and health are not even across the U.S.
MDedge Infectious Disease